Quintiles Expands Commercial Services in Rapidly Growing Pharma Market of Middle East and North Africa

Quintiles Expands Commercial Services in Rapidly Growing Pharma Market of Middle East and North Africa
Signs Strategic Partnership with Dayarn Pharma

February 14, 2012

RESEARCH TRIANGLE PARK, N.C.--(EON: Enhanced Online News)--Quintiles is extending its global footprint to provide commercial services in the Middle East and North Africa (MENA) region through an agreement with Dayarn Pharma, a United Arab Emirates (UAE)-based company that specializes in biopharmaceutical sales, marketing and regulatory efforts needed to maximize brands in the Arab Gulf region.

"We are proud to be working alongside Quintiles to offer high quality commercialization services to support multi-national pharmaceutical companies looking to expand into new geographies. With this deal, we are strengthening our ability to be the partner of choice for multinational biopharmaceutical and healthcare companies in MENA."

The partnership will allow Quintiles and its joint venture partners in the region to deliver pharmaceutical contract sales force and sales promotion outsourcing services to customers looking to accelerate outcomes by working in new geographies including Saudi Arabia, UAE, Qatar, Oman, Kuwait, Lebanon, Jordan, Morocco, Algeria and Tunisia. The partnership reinforces Quintiles existing presence in the region following establishment of joint ventures in Turkey in 2007 and Egypt in 2010.

James Featherstone, Senior Vice President of Commercial Services at Quintiles, said: "There is significant growth in the Middle East and North Africa market, with Saudi Arabia, UAE, Algeria and Egypt standing out as the largest markets in terms of projected growth potential and value. There is strong demand for services in the region from our biopharma customers seeking to expand their geographic footprint while minimising risk.

"The pharma market in MENA is growing at an annual rate of 12% to 15%, with significantly higher growth in the novel, patented product segment. Countries currently spend 6% of their GDP on public healthcare and this is forecasted to nearly double to 11.6% over the next decade. Dayarn brings a wealth of expertise and experience in delivering the high quality sales and marketing solutions to maximize brands to their full potential."

Omar Khan, CEO of Dayarn Pharma said: "We are proud to be working alongside Quintiles to offer high quality commercialization services to support multi-national pharmaceutical companies looking to expand into new geographies. With this deal, we are strengthening our ability to be the partner of choice for multinational biopharmaceutical and healthcare companies in MENA."

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Contacts

Quintiles
Media Relations
Laura Wilson, +44-118-4508392
[email protected]
or
Investor Relations
Greg Connors, +1-919-998-2000
[email protected]

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.